Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
Type:
Application
Filed:
May 8, 2020
Publication date:
August 27, 2020
Applicant:
CURASIGHT APS
Inventors:
Andreas KJAER, Morten PERSSON, Jacob MADSEN
Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
Type:
Grant
Filed:
November 29, 2013
Date of Patent:
February 6, 2018
Assignee:
CURASIGHT APS
Inventors:
Andreas Kjaer, Morten Persson, Jacob Madsen
© 2026 Justia
